The world of medicine has made incredible progress in treating blood cancers, such as leukemia and lymphoma. However, treating solid tumors, like those found in the lungs, breasts, or ovaries, is still a major challenge. For many patients, the current options simply aren't enough. At a recent gathering of global leaders, a new company called Equaly shared a breakthrough that could change how we fight these difficult cancers using the body’s own immune system.
The Problem: The Tumor’s "Invisible Shield"
The biggest reason solid tumors are so hard to treat is that they don’t just sit there; they build a protective wall around themselves. Doctors call this the Tumor Microenvironment (TME). Imagine it as a fortress made of different types of cells that block the body’s natural "soldier" cells from getting inside.
Because of this fortress, these tumors are often called "cold". This means they are invisible or "hidden" from the immune system. For a treatment to work, doctors need a way to turn these "cold" tumors into "hot" ones, essentially setting off an alarm that tells the whole immune system exactly where the cancer is hiding.
Equaly’s founder and lead scientist, Jean-Marie Saint-Remy, is a highly experienced researcher with a medical degree and a PhD in Immunology. Over his distinguished career, which includes serving as a Full Professor at the University of Leuven (KUL), he has published more than 150 scientific articles and founded biotech companies that are now in advanced clinical trials for diseases like diabetes and multiple sclerosis. It was through this extensive research that he identified a unique type of cell in our bodies capable of finding and attacking hidden tumors: Natural Killer T (NKT) cells specific for peptides, by opposition to lipid-specific invariant NKT cells.
Unlike other immune cells that have to be "taught" how to fight a specific person's cancer, these NKT cells have unique, universal powers:
- They are ready for everyone: These cells are found in the blood of every healthy person.
- They use a universal "key": To attack a tumor, these cells look for a specific marker (called CD1d). Because this marker is the same in almost every human being, the treatment is highly predictable and doesn't depend on a patient's unique genetic makeup.
- They act instantly: The moment these cells touch a tumor, they start releasing chemical signals that act like a flare gun, calling for a massive backup of other immune cells to join the fight.
- They create a "memory": Once the fight is over, the immune system "remembers" the cancer, which helps protect the patient from it coming back in the long term.
The Target: A Common Flaw in 60% of Cancers
Equaly is currently focusing on a specific target called p53. You can think of p53 as a "master switch" in our cells that helps prevent cancer. When this switch breaks (mutates), cancer can grow.
This mutation is found in more than 60% of all human tumors. Because it is so common, Equaly's technology is "organ-agnostic," meaning it could potentially work on many different types of cancer regardless of where they are in the body. In the lab, Equaly has already shown that their NKT cells can successfully find and destroy human ovarian cancer cells.
A New Way to Deliver Treatment
Equaly is working on two main ways to bring this technology to patients:
- High-Tech Vaccines: These would use small particles (similar to the technology used in some modern vaccines) to "wake up" and grow the patient's own NKT cells inside their body.
- "Ready-to-Use" Cell Therapy: Because NKT cells are so universal, Equaly can create a treatment that is "off-the-shelf". This means a doctor could give the treatment to a patient immediately without the long wait times or the risk of the patient's body rejecting the cells.
This approach represents a fundamental shift in how we care for cancer patients. By using the body’s innate "scouts" and turning them into precision killers, Equaly is paving a path toward treatments that are more effective and less toxic than traditional methods.
The company expects to move into the official testing phase with the government (obtaining an IND) within the next two to three years. For patients with solid tumors that have been hard to treat, this "game-changer" offers a much-needed glimpse into the future of medicine.
